Plain-English translation of NCT06383780 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether combining Tislelizumab (an immunotherapy drug) with one of two different chemotherapy regimens works better to treat nasopharyngeal cancer that has spread to the bones. The study will compare how well patients respond to either the GP chemotherapy combination or the TPC chemotherapy combination, each paired with this medication. Researchers want to find the most effective first-line treatment option for patients with this advanced cancer.
Nasopharyngeal cancer that has spread to the bones is difficult to treat, and doctors need better options for patients who cannot undergo surgery or radiation therapy. This trial is testing whether adding immunotherapy to chemotherapy can improve outcomes for these patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of the two chemotherapy combinations paired with Tislelizumab immunotherapy. You will attend regular clinic visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and check for side effects. The treatment will continue over several months, with your doctor adjusting the plan based on how your cancer responds and how you tolerate the medications.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China